TheraRadar
Data updated: May 26, 2026

NICARDIPINE HYDROCHLORIDE

Cardiovascular Approved 1996-07-18

Nicardipine hydrochloride treats chronic stable angina, specifically chest pain triggered by physical exertion. It is also used for patients with high blood pressure and can be taken alone or combined with other medications like beta-blockers. When managing hypertension, it is important to monitor the drug's effect due to variations in blood pressure levels between doses.

Source: FDA Label • MANKIND PHARMA

How NICARDIPINE HYDROCHLORIDE Works

This drug works by blocking calcium ions from entering cardiac and vascular smooth muscle cells through specific channels. It is more selective for blood vessels than the heart muscle, allowing it to relax coronary vascular smooth muscle without significantly affecting the heart's pumping strength. This process happens without altering the concentration of calcium in the blood.

18
Indications
--
Phase 3 Trials
29
Years on Market

NICARDIPINE HYDROCHLORIDE Approval History

1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
118 FDA actions from 1996 to 2026
Mar 2026 SUPPL
Label · Labeling
Dec 2025 SUPPL
Mfg · Manufacturing (CMC)
Oct 2025 ORIGINAL
Update

What NICARDIPINE HYDROCHLORIDE Treats

2 indications

NICARDIPINE HYDROCHLORIDE is approved for 2 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Angina
  • Hypertension
Source: FDA Label

NICARDIPINE HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 12 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to NICARDIPINE HYDROCHLORIDE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMLODIPINE BESYLATE AND VALSARTAN
AMLODIPINE BESYLATE
2 shared
Viatris
Shared indications:
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
AMLODIPINE BESYLATE
2 shared
Teva
Shared indications:
CADUET
AMLODIPINE BESYLATE
2 shared
PHARMACIA
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT03098680 PRIME PRIME (A094136) Ph 1 terminated A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
NCT01810302 results posted 034-2013 Ph 2 terminated Safety Study of Nicardipine to Treat Cerebral Vasospasm
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NICARDIPINE HYDROCHLORIDE FDA Label Details

Indications & Usage

FDA Label (PDF)

NICARDIPINE HYDROCHLORIDE is indicated for the treatment of Angina; Hypertension.

Looking for the branded version?

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE

Full clinical data, patents, trials, and competitive landscape for nicardipine hydrochloride.

See NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.